Studies have shown that low NAD+ levels are associated with neurodegenerative diseases. Therefore, restoring/increasing NAD+ levels in the body has become an important intervention against age-related neurodegenerative diseases. One of the most widely studied methods of increasing NAD+ levels in the body is through the use of NAD+ precursors such as Nicotinamide Mononucleotide (NMN). Several previous studies have shown that NMN has a protective effect on the brain and can improve cognitive dysfunction and reduce neuroinflammation in vivo and in vitro. Studies have confirmed that oral administration of NMN can increase NAD+ levels in the brains of mice.
Recent studies have proven:
1. NMN intervention can improve learning and memory impairment in aging rats through relevant pathways;
2. NMN can be used as a potential therapeutic drug to combat learning and memory impairment induced by environmental pollutants;
3. NMN intervention can alleviate memory dysfunction and neuronal damage caused by sepsis, and attenuate the inflammatory response and oxidative stress in the hippocampus region of mice.
In fact, since the discovery of NAD+ in 1906, NMN has attracted the attention of scientists due to its richness in the body and its key role in maintaining human health. In numerous previous studies, increasing NAD+ levels in the body has shown promising results in areas such as metabolism and age-related diseases, and has even shown some anti-aging properties.